ClinicalTrials.gg
Not yet recruitingNCT07301502Updated Dec 24, 2025

A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease

A Phase 1 interventional study of AK152 and Placebo in Alzheimer' s Disease, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
82nd of 176
108 · median 100
Started
2025
with 39 others
Phase 1
26 of 260
18 open now
Primary completion
2027-06
later than 76 of 161 live
Registered
211th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 82nd largest by planned enrollment of the 176 interventional ones that give a count, is one of 40 that started in 2025, is one of 26 in phase 1, reaches primary completion later than 76 of the 161 other live ones, and was the 211th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind phase I clinical trial to evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AK152 in Healthy Volunteers and Patients with Alzheimer' s Disease.

Read the detailed description

This is a randomized, double-blind phase I clinical trial to evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AK152 in Healthy Volunteers and Patients with Alzheimer' s Disease. Subjects will be randomized to receive AK152 regimen or placebo treatment.

03

Conditions studied

  • Alzheimer' s Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria - Part 1 (Healthy Volunteers):

  1. Healthy male or female subjects aged 18 to 40 years (inclusive) at the time of signing the form (ICF).
  2. Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; (BMI) = weight (kg) / height² (m²) within the range of 19.0-26.0 kg/m² (inclusive).
  3. Subjects agree to take protocol-specified measures and refrain from donating sperm or oocytes from signing the ICF through the treatment period and for at least 90 days after the last administration of study drug; women of must be non-pregnant and non-lactating.
  4. Subjects are able to understand and voluntarily sign a written ICF before any study-specific procedures are performed, and are able to comply with the study procedures and follow-up requirements.

Key Exclusion Criteria - Part 1 (Healthy Volunteers):

  1. Known allergy to components of AK152 injection or any monoclonal antibody, or high risk of allergy.
  2. History or presence of any systemic disease that may interfere with study results.
  3. abnormalities in vital signs at screening or prior to randomization.
  4. Clinically significant laboratory abnormalities at screening or prior to randomization per investigator judgment.
  5. Use of any medication (including prescription, OTC, herbal medicines, dietary supplements) within 4 weeks before randomization or within 5 half-lives of the medication (whichever is longer), or planned use during the study.
  6. History of frequent alcohol consumption within 24 weeks or inability to abstain during inpatient stay.
  7. Drug abuse or positive urine drug screen at screening.
  8. Smokers consuming >5 cigarettes/day within 12 weeks prior to screening or unable to abstain during the inpatient period.
  9. Excessive intake of tea, coffee, or other caffeine-containing beverages.

Key Inclusion Criteria - Part 2 (Alzheimer' s Disease Patients):

  1. Able to understand and voluntarily sign a written ICF before any study-specific procedures are performed, and able to comply with study procedures and follow-up requirements.
  2. Aged 50 to 85 years (inclusive) at the time of signing the ICF.
  3. BMI within 17.0-35.0 kg/m² (inclusive).
  4. Subjects agree to take protocol-specified contraception measures and refrain from donating sperm or oocytes from signing the ICF through the treatment period and for at least 90 days after the last dose; women must be non-pregnant and non-lactating.
  5. The subject must have an identified trial partner who must sign a separate ICF.
  6. Meets the 2011 NIA-AA core clinical criteria for MCI due to AD or mild AD dementia.
  7. Evidence of brain amyloid deposition confirmed by Aβ-PET/CT at screening.

Key Exclusion Criteria - Part 2 (Alzheimer' s Disease Patients):

  1. History or evidence of involving any organ system within 5 years prior to screening, regardless of treatment or remission status (except completely cured carcinoma in situ of the cervix, non- squamous cell carcinoma of the skin, or basal cell carcinoma).
  2. Severe or unstable disease at screening or prior to randomization that may affect study assessments.
  3. Major neurological disorder (other than AD) that may affect cognition or ability to complete study procedures.
  4. (TIA) or stroke within 12 months prior to randomization.
  5. Clinically significant abnormalities on brain MRI at screening.
  6. Known allergy to components of AK152 injection or any monoclonal antibody, or high risk of allergy.
  7. History of alcohol or drug abuse within 2 years prior to screening or prior to randomization.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    AK152 regimen

    Drug: AK152

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAK152

    Subjects receiving single or multiple doses of AK152 injection.

  • DrugPlacebo

    Subjects receiving single or multiple doses of placebo injection.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    The incidence of AEs.

    Time frame: Up to approximately 8 weeks after the last dose

Secondary outcomes

  1. Peak concentration (Cmax)

    Measure and assess the Cmax of AK152.

    Time frame: Up to approximately 8 weeks after the last dose

  2. Time to peak (Tmax)

    Measure and assess the Tmax of AK152.

    Time frame: Up to approximately 8 weeks after the last dose

  3. Area under the curve (AUC)

    Measure and assess the AUC of AK152.

    Time frame: Up to approximately 8 weeks after the last dose

  4. Half-life (t1/2)

    Measure and assess the t1/2 of AK152.

    Time frame: Up to approximately 8 weeks after the last dose

  5. Immunogenicity characteristics of AK152

    Number and percentage of subjects with detectable anti-drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.

    Time frame: Up to approximately 8 weeks after the last dose

07

Study locations

1 site
  • The Frist Affiliated Hospital of USTC
    Hefei, Anhui, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jun 2027, 18 months later.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 18 months is above that.

Counting every sponsor, half of 234 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 24, 2025
StartEst.
Dec 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301502
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Dec 2025 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 24, 2025

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 3998

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion